Takeda Buys into Viral Immunology with US$1 B Turnstone Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)
Published: 24 Dec-2019
DOI: 10.3833/pdr.v2019.i12.2480 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an effort to build its immuno-oncology franchise, Takeda Pharmaceutical has entered into a strategic collaboration with Turnstone Biologicsto develop products from Turnstone’s proprietary vaccinia virus platform targeting a broad range of cancer indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS